11 reports

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Neck Cancer
  • France
  • Germany
  • United States
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Neck Cancer
  • France
  • Germany
  • Italy
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • United States
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • Japan
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • Germany
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • Italy
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • United Kingdom
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • France
  • Market Size

Head & Neck Cancers Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • Spain
  • Market Size

Head & Neck Cancer Pipeline Highlights – 2017 ##.

  • Cancer
  • Neck Cancer
  • Pathology
  • Product Initiative
  • NBTXR3 - HEAD & NECK CANCER
  • NBTXR3 - HEAD & NECK CANCER - PRODUCT DESCRIPTION

Summary Nanobiotix S.A. (Nanobiotix) is a nanomedicine company that develops tools for local treatment of cancer. The company is developing product portfolio that consists of three products designed to meet specific clinical needs for different cancers, which include NBTXR3, NBTX IV, and TOPO NBTX. Its NBTXR3 nanoparticles are...

  • Cancer
  • Neck Cancer
  • United States
  • Product Initiative
  • Nanobiotix